BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ichikawa W, Sasaki Y. Challenges in predicting the clinical outcome in S-1-based chemotherapy for gastric cancer patients. Int J Clin Oncol 2008;13:206-11. [DOI: 10.1007/s10147-008-0786-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Izuishi K, Haba R, Kushida Y, Kadota K, Takebayashi R, Sano T, Usuki H, Hossain MA, Mori H, Masaki T, Suzuki Y. S-1 and the treatment of gastric cancer with peritoneal dissemination. Exp Ther Med 2011;2:985-90. [PMID: 22977609 DOI: 10.3892/etm.2011.290] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
2 Ruwali M, Pant MC, Shah PP, Mishra BN, Parmar D. Polymorphism in cytochrome P450 2A6 and glutathione S-transferase P1 modifies head and neck cancer risk and treatment outcome. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2009;669:36-41. [DOI: 10.1016/j.mrfmmm.2009.04.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
3 Nakamura A, Hayashi K, Nakajima G, Kamikozuru H, Okuyama R, Kuramochi H, Hatori T, Yamamoto M. Impact of dihydropyrimidine dehydrogenase and γ-glutamyl hydrolase on the outcomes of patients treated with gemcitabine or S-1 as adjuvant chemotherapy for advanced pancreatic cancer. Exp Ther Med 2011;2:1097-103. [PMID: 22977627 DOI: 10.3892/etm.2011.340] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
4 He MM, Zhang DS, Wang F, Wang ZX, Yuan SQ, Wang ZQ, Luo HY, Ren C, Qiu MZ, Jin Y, Wang DS, Chen DL, Zeng ZL, Li YH, He YY, Hao YT, Guo P, Wang FH, Zeng YX, Xu RH. Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway. Cancer Chemother Pharmacol 2017;79:69-79. [PMID: 27913881 DOI: 10.1007/s00280-016-3209-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
5 Govindan R, Morgensztern D, Kommor MD, Herbst RS, Schaefer P, Gandhi J, Saito K, Zergebel C, Schiller J. Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011;6:790-5. [PMID: 21325974 DOI: 10.1097/JTO.0b013e3182103b51] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
6 Álvarez P, Marchal JA, Boulaiz H, Carrillo E, Vélez C, Rodríguez-Serrano F, Melguizo C, Prados J, Madeddu R, Aranega A. 5-Fluorouracil derivatives: a patent review. Expert Opin Ther Pat. 2012;22:107-123. [PMID: 22329541 DOI: 10.1517/13543776.2012.661413] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
7 Zhu Z, Gong YB, Xu HM. Neoadjuvant therapy strategies for advanced gastric cancer: Current innovations and future challenges. Chronic Dis Transl Med 2020;6:147-57. [PMID: 32908968 DOI: 10.1016/j.cdtm.2020.03.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]